- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06346886
HTN App for HTN Control and Cardiovascular Health Among African-Americans
February 24, 2026 updated by: LaPrincess C. Brewer, Mayo Clinic
FAITH! Hypertension App to Improve Hypertension Control and Cardiovascular Health Among African-Americans: A Decentralized Randomized Clinical Trial
The purpose of this study is to test the hypertension (HTN) app-based intervention to see if it is more effective in improving uncontrolled HTN and HTN self-care among Africian-Americans from baseline to post-intervention (immediate, 3 months and 6 months post-intervention) as compared to the standard of care.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lainey Moen
- Phone Number: 507-266-7062
- Email: Moen.Lainey@mayo.edu
Study Contact Backup
- Name: Ashton Krogman
- Phone Number: 507-266-2087
- Email: krogman.ashton@mayo.edu
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic
-
Contact:
- Lainey Moen
- Phone Number: 507-266-7062
- Email: Moen.Lainey@mayo.edu
-
Contact:
- Ashton Krogman
- Phone Number: (507) 266-2087
- Email: Krogman.Ashton@mayo.edu
-
Principal Investigator:
- LaPrincess Brewer, M.D., M.P.H.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- African-American (AA) adults that are established patients at Neighborhood HealthSource in Minneapolis, Minnesota.
- Receives primary care (i.e., has designated primary care provider) at the partnering FQHCs and intent to continue care there for next 12 months
- African American race/ethnicity
- Men and women aged ≥18 years
- Uncontrolled HTN (defined as Stage 2 HTN with a BP ≥140/90 mmHg [as per 2017 American College of Cardiology/American Heart Association HTN Guidelines32] at most recent outpatient evaluation, with or without BP medications)
- Documented diagnosis of HTN in EHR
- At least 1 office visit at the partnering FQHCs in the prior year
- Smartphone ownership (supporting iOS or Android Systems)
- Active email address and willingness to utilize it throughout the study
- Basic Internet navigation skills (for example, can search for information on websites, open and send emails)
- Access to the Internet on at least a weekly basis (such as at home, a family member's or friend's home, church, library/community center, school/university, Internet café, etc.)?
Exclusion Criteria:
- Diagnosis of a serious medical condition or disability that would make participation difficult (i.e. visual or hearing impairment, mental disability that would preclude independent use of the app).
- No primary care provider at partnering FQHC
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention Group
African American adults with uncontrolled hypertension (HTN) will be assigned to complete an 11 week guided intervention using the FAITH!
HTN app.
|
Participants will remain in the intervention for 11 weeks.
The app-based intervention is a tailored program to promote HTN self-management and knowledge through an 11-module educational video series with a focus on HTN.
Participants will also be provided with at home Blood Pressure (BP) monitoring system to allow for self-tracking of BP measurements(automatically synchronized with the app).
The app will include pre-post module quizzes, a tracking component for participants to input self-monitored measures (medication adherence, diet, physical activity, etc.).
The app sharing board will be a moderated discussion platform and feed for participant interaction by posting healthy lifestyle practices through text, photographs and video to foster discussion on HTN management barriers/facilitators.
The project team will post weekly to the sharing board on HTN-related topics to generate discussion among patients.
|
|
No Intervention: Control Group
African American adults with uncontrolled hypertension (HTN) will receive the standard of care of HTN management.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Absolute Change in Systolic Blood Pressure (BP)
Time Frame: Baseline, immediate post intervention
|
Systolic BP (mmHg) will be measured as an average of 3 sitting readings with an oscillometric automated device during in-clinic health assessments.
|
Baseline, immediate post intervention
|
|
HTN Self-Care as reported by H-SCALE(HTN Self-Care Activity Level Effects)
Time Frame: Baseline, immediate, 3 months, 6 months post intervention
|
The H-SCALE is a 31-item instrument that assesses 6 HTN behavioral self-care activities recommended for optimal HTN management (BP medication adherence, weight loss/ideal body weight maintenance, adoption of a low-salt diet, regular physical activity for ≥30 minutes/day, limiting alcohol intake, and ceasing tobacco use).
|
Baseline, immediate, 3 months, 6 months post intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of subjects reaching BP control
Time Frame: Immediate, 3 months, 6 months post intervention
|
Proportion of subjects reaching BP control (defined as meeting target BP of <140/90 mmHg)
|
Immediate, 3 months, 6 months post intervention
|
|
Change in BP as assessed by home BP cuff measurements
Time Frame: Baseline, immediate post intervention
|
BP (mmHg) will be measured 3 times per week during the 11-week intervention period using a home BP monitoring system.
The 3 weekly measurements will be averaged and average weekly BP will be compared from baseline to immediate post intervention to determine the change in BP.
This outcome is only evaluated in the intervention group as the control group will not undergo home BP cuff measurements.
|
Baseline, immediate post intervention
|
|
CV Health Knowledge as measured by module assessment scores
Time Frame: Immediate post intervention
|
Change in percentage correct scores (pre- and post- self-assessments) for each education module by patient and as a conglomerate (mean) for all patients.
|
Immediate post intervention
|
|
Hypertension (HTN) Knowledge as assessed by 11-item questionnaire
Time Frame: Baseline, immediate post intervention
|
HTN Knowledge will be assessed using a previously validated 11-item questionnaire which asks participants questions about the definition, prevention, management and complications of hypertension.
Responses are record as true, false or uncertain to each question with true response receiving a score of 1 and false or uncertain responses receiving a score of 0. Total scores on the questionnaire range from 0-11 with higher scores reflecting better HTN knowledge.
|
Baseline, immediate post intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: LaPrincess Brewer, M.D., M.P.H, Mayo Clinic
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 15, 2025
Primary Completion (Estimated)
November 1, 2026
Study Completion (Estimated)
November 1, 2026
Study Registration Dates
First Submitted
March 29, 2024
First Submitted That Met QC Criteria
March 29, 2024
First Posted (Actual)
April 4, 2024
Study Record Updates
Last Update Posted (Actual)
February 27, 2026
Last Update Submitted That Met QC Criteria
February 24, 2026
Last Verified
February 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 23-011703
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.